Testing a new naltrexone implant for treating methamphetamine use disorder.
Official title: Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD).
Funded at Biocorrx Pharmaceuticals INC · NIH-11042242 · Data updated 2026-11-12
This study is looking at a new long-lasting implant that delivers medication to help people with Methamphetamine Use Disorder stay off meth, either on its own or with another medication, to see how well it works and if it's safe for you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biocorrx Pharmaceuticals INC NIH-funded |
| Lab location | 1 site (Anaheim, United States) |
| Project start | March 1, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $3,274,441 |
| NIH project number | 5U01DA059994-02 |
| Project ID | NIH-11042242 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with Methamphetamine Use Disorder who are seeking treatment.
✕Less likely to help
Patients who are not diagnosed with Methamphetamine Use Disorder or those who are currently using other forms of treatment may not benefit from this research.
What this research studies
This research investigates the use of BICX104, a long-lasting naltrexone implant, either alone or combined with bupropion, to treat individuals with Methamphetamine Use Disorder (MUD). The study aims to evaluate the safety and effectiveness of this treatment approach, which could help maintain abstinence from methamphetamine use. By using a subcutaneous implant, the research seeks to improve patient compliance compared to traditional oral medications, ensuring consistent therapeutic levels of the drug. Participants will be compared against a placebo group to assess the benefits of the treatment.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for individuals struggling with methamphetamine addiction.
How similar studies have gone: Previous studies have shown promise in using naltrexone for substance use disorders, but this specific approach with BICX104 is novel.
Where this research is happening
-
Biocorrx Pharmaceuticals INC
Anaheim, United States Active
Researchers
- Principal investigator: Beebe Devarney, Katherine — Biocorrx Pharmaceuticals INC
- Study coordinator: Beebe Devarney, Katherine
Related research
Other NIH-funded projects on the same topics.
-
Calming cue-triggered cravings in methamphetamine use
Seeing if teaching people with methamphetamine use disorder a thinking-based skill (cognitive reappraisal) can reduce brain and craving reactions to drug cues.
-
Psilocybin for treatment of methamphetamine use disorder
A study is testing whether psilocybin can help people with methamphetamine use disorder feel better and stay abstinent, starting with a small, carefully monitored group.
-
Reducing Methamphetamine Use to Improve Health and Well-Being
A clinical trial tests whether giving incentives to people with methamphetamine use disorder helps them use less meth and improves heart, immune, sleep, and psychosocial health.
-
Mobilizing Recovery Resources to Improve HIV Care for People Using Methamphetamine
A patient-friendly project to help people living with HIV who use methamphetamine strengthen personal and community supports to stay engaged in care.
-
Psilocybin-assisted therapy for methamphetamine use disorder in people with HIV
A small, carefully controlled study will test whether psilocybin, given with support, can help people living with HIV who have moderate-to-severe methamphetamine use disorder.
-
Tirzepatide for Methamphetamine Use Disorder in adults with diabetes
A study will test whether an approved diabetes drug, tirzepatide, helps adults with methamphetamine use disorder who have diabetes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.